Reber Genetics Co., Ltd., a leading animal vaccine research and development company, is pleased to announce its successful participation in the 11th Asian Pig Veterinary Society Congress (APVS), held from November 9 to 12, 2025, at the Fukuoka International Congress Center in Japan.
This exhibition marked a significant step for Reber Genetics to showcase its R&D capabilities on the international stage and expand global collaboration. During the four-day congress, Reber Genetics' dedicated booth attracted veterinarians, scholars, swine disease experts, and industry partners from across Asia and the world for fruitful discussions and exchanges.
Exhibition Highlights and Collaboration Outcomes
Deepening International Partnership: Reber Genetics conducted in-depth business meetings with its established Japanese strategic partner, Meiji Animal Health Co., Ltd., at the venue. Discussions focused on how to more effectively promote Reber Genetics' high-quality swine vaccine products to the Japanese and Asia-Pacific markets, offering local pig farmers more comprehensive disease prevention solutions.
-
New Technology Exchange: The company’s technical team engaged in professional and enthusiastic discussions with numerous domestic and international industry professionals. In addition to showcasing popular core products, such as the CIRCOQ vaccine for Porcine Circovirus Type 2 (PCV2), Reber Genetics also unveiled several innovative vaccine pipelines currently in clinical trial phases. The forward-looking technology and product potential garnered wide attention and recognition from attending experts.
-
Enhancing Brand Visibility: Through this APVS, Reber Genetics not only successfully demonstrated Taiwan's cutting-edge technology and manufacturing prowess in the animal vaccine sector but also further solidified the company's professional standing in the field of swine health in Asia.
Dr. Frank CJ. Chang, Chief Technology Officer of Reber Genetics, stated: "The 2025 APVS provided us with an excellent platform to interact face-to-face with global top swine disease experts and collaboratively address industry challenges. The new contacts we established and the feedback we received at this congress are crucial for the future optimization of our products and our global market deployment. Reber Genetics remains committed to innovation, aiming to provide more effective and safer vaccines to promote the sustainable development of the swine industry in Asia and worldwide."
Looking Ahead
Reber Genetics extends its gratitude to all international visitors and partners who visited our booth. Moving forward, the company will continue to invest resources in animal vaccine R&D and international market expansion. Through continuous technological innovation and industry collaboration, we aim to make greater contributions to global swine health management.
About Reber Genetics Co., Ltd.:
Reber Genetics Co., Ltd. is a leading Taiwanese animal vaccine R&D and manufacturing company. With a long-term focus on animal health, Reber Genetics is dedicated to developing safe, effective, and cost-efficient vaccine products to solve major disease challenges facing the pig farming industry, ensuring global food security and animal welfare.